Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma
DOI:
https://doi.org/10.2340/00015555-3155Keywords:
localized scleroderma, morphea, scleroderma, treatment, methotrexateAbstract
Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho?trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho?trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho?trexate and we did not identify a clinical profile for those resistant patients.Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Juliette Hardy, Franck Boralevi, Stéphanie Mallet, Natalia Cabrera, Alexandre Belot, Alice Phan, Sébastien Barbarot, Audrey Duriez-Lasek, Christine Chiaverini, Thomas Hubiche, Emmanuel Mahé, Edouard Bégon, Emmanuelle Bourrat, Olivia Boccara, Hélène Aubert, Martine Grall Lerosey, Catherine Droitcourt, Maryam Piram, Juliette Mazereeuw-Hautier, and Research Group of the French Society of Paediatric Dermatology (SDFP in French)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
